MedTrace Logo

Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor

NCT07743554 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-08-04

No results posted yet for this study

Summary

The purpose of this study is to learn whether the study drugs avutometinib and defactinib can help stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery.

Conditions

  • MPNST (Malignant Peripheral Nerve Sheath Tumor)

Interventions

DRUG

avutometinib capsule + defactinib tablet

avutometinib in combination with defactinib in participants with metastatic or unresectable MPNST

Sponsors & Collaborators

Principal Investigators

  • Girish Dhall, MD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-01
Primary Completion
2031-01-31
Completion
2032-01-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743554 on ClinicalTrials.gov